医疗医学早期乳腺癌进展 青岛.pptVIP

小结 烷化剂+抗代谢类联合 蒽环+烷化剂 紫杉+蒽环+烷化剂 紫杉+蒽环+烷化剂+抗代谢类 具体方案的选择（组合、个性与共性） 肿瘤的类型 （临床病理、分子标志） 肿瘤的亚类型（分子标志、基因类型） * For more information on this study, go online to: /Oncology/Conference%20Coverage/Breast%20Cancer%20Dec%202010/Tracks/Early%20Breast%20Cancer/Capsules/S4-3.aspx * * * USO 9735 是一项III期研究,评估了泰索帝-环磷酰胺的疗效和安全性. 目的在于观察非蒽环类方案和标准的蒽环联合方案相比较用于可手术的乳腺癌病人. * With a median follow-up of 7 years, disease-free survival remains significantly increased with TC. The reduction in risk of recurrence approximated 26%. The rates of DFS at 7 years were 81% in the TC arm and 75% in the AC arm. The benefit of TC